This Article Full Text Full Text (PDF) All Versions of this Article: 35/1/2    most recent 01.STR.0000109041.89959.4Cv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meisel, C. Articles by Meisel, A. Search for Related Content PubMed PubMed Citation Articles by Meisel, C. Articles by Meisel, A.

(Stroke. 2004;35:2.)
© 2004 American Heart Association, Inc.

Expedited Publication

Preventive Antibacterial Treatment Improves the General Medical and Neurological Outcome in a Mouse Model of Stroke

Christian Meisel, MD; Konstantin Prass, MD; Johann Braun, MD; Ilya Victorov, MD; Tilo Wolf, MD; Dirk Megow, PhD; Elke Halle, MD; Hans-Dieter Volk, MD; Ulrich Dirnagl, MD Andreas Meisel, MD

From the Departments of Neurology (K.P., J.B., T.W., D.M., U.D., A.M.), Medical Immunology (C.M., H.-D.V.), and Microbiology (E.H.), Medical Faculty Charité, Humboldt-University, Berlin, Germany, and Brain Research Institute, Russian Academy of Sciences, Moscow, Russia (I.V.).

Reprint requests to Dr Andreas Meisel, Department of Neurology, Humboldt-University Berlin, Schumannstr 20–21, 10098 Berlin, Germany. E-mail andreas.meisel{at}charite.de

Background and Purpose— Epidemiological studies have demonstrated a high incidence of infections after severe stroke and their prominent role in morbidity and mortality in stroke patients. In a mouse model, it has been shown recently that stroke is coupled with severe and long-lasting immunosuppression, which is responsible for the development of spontaneous systemic infections. Here, we investigated in the same model the effects of preventive antibiotic treatment on survival and functional outcome of experimental stroke.

Methods— Mice were subjected to experimental stroke by occlusion of the middle cerebral artery (MCAO) for 60 minutes. A group of mice received moxifloxacin (6x100 mg/kg body weight every 2 hours over 12 hours) either immediately or 12 hours after MCAO. Control animals received the vector only. Behavior, neurological deficit, fever, survival, and body weight were monitored over 14 days. In a subgroup, infarct volume was measured 4 days after MCAO. Microbiological assessment was based on cultures of lung tissue, blood, and feces of animals 3 days after stroke. For a dose-response study, moxifloxacin was given immediately after MCAO in different doses and at different time points.

Results— Microbiological analyses of blood and lung tissue demonstrated high bacterial burden, mainly Escherichia coli, 3 days after stroke. Accordingly, we observed clinical and histological signs of septicemia and pneumonia. Moxifloxacin prevented the development of infections and fever, significantly reduced mortality, and improved neurological outcome.

Conclusions— Preventive antibiotic treatment may be an important new therapeutical approach to improve outcome in patients with severe stroke.

Key Words: antibiotics • pneumonia • stroke • mice

This article has been cited by other articles:

				J. R. Caso, O. Hurtado, M. P. Pereira, B. Garcia-Bueno, L. Menchen, L. Alou, M. L. Gomez-Lus, M. A. Moro, I. Lizasoain, and J. C. Leza Colonic bacterial translocation as a possible factor in stress-worsening experimental stroke outcome Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2009; 296(4): R979 - R985. [Abstract] [Full Text] [PDF]

				A. Chamorro, X. Urra, and A. M. Planas Infection After Acute Ischemic Stroke: A Manifestation of Brain-Induced Immunodepression Stroke, March 1, 2007; 38(3): 1097 - 1103. [Abstract] [Full Text] [PDF]

				U. Dirnagl, J. Klehmet, J. S. Braun, H. Harms, C. Meisel, T. Ziemssen, K. Prass, and A. Meisel Stroke-Induced Immunodepression: Experimental Evidence and Clinical Relevance Stroke, February 1, 2007; 38(2): 770 - 773. [Abstract] [Full Text] [PDF]

				J. M. Gee, A. Kalil, C. Shea, and K. J. Becker Lymphocytes: Potential Mediators of Postischemic Injury and Neuroprotection Stroke, February 1, 2007; 38(2): 783 - 788. [Abstract] [Full Text] [PDF]

				K. Prass, J. S. Braun, U. Dirnagl, C. Meisel, and A. Meisel Stroke Propagates Bacterial Aspiration to Pneumonia in a Model of Cerebral Ischemia Stroke, October 1, 2006; 37(10): 2607 - 2612. [Abstract] [Full Text] [PDF]

				V. Rajajee, C. Kidwell, S. Starkman, B. Ovbiagele, J. R. Alger, P. Villablanca, F. Vinuela, G. Duckwiler, R. Jahan, A. Fredieu, et al. Early MRI and outcomes of untreated patients with mild or improving ischemic stroke. Neurology, September 26, 2006; 67(6): 980 - 984. [Abstract] [Full Text] [PDF]

				M. Vargas, J. P. Horcajada, V. Obach, M. Revilla, A. Cervera, F. Torres, A. M. Planas, J. Mensa, and A. Chamorro Clinical Consequences of Infection in Patients With Acute Stroke: Is It Prime Time for Further Antibiotic Trials? Stroke, February 1, 2006; 37(2): 461 - 465. [Abstract] [Full Text] [PDF]

				A. Chamorro and J. Hallenbeck The Harms and Benefits of Inflammatory and Immune Responses in Vascular Disease Stroke, February 1, 2006; 37(2): 291 - 293. [Full Text] [PDF]

				M. Hermier, N. Nighoghossian, L. Derex, M. Wiart, C. Nemoz, Y. Berthezene, and J. C. Froment Hypointense leptomeningeal vessels at T2*-weighted MRI in acute ischemic stroke Neurology, August 23, 2005; 65(4): 652 - 653. [Full Text] [PDF]

				A. Chamorro, J.P. Horcajada, V. Obach, M. Vargas, M. Revilla, F. Torres, A. Cervera, A.M. Planas, and J. Mensa The Early Systemic Prophylaxis of Infection After Stroke Study: A Randomized Clinical Trial Stroke, July 1, 2005; 36(7): 1495 - 1500. [Abstract] [Full Text] [PDF]

				V. Thijs More bad news about atrial fibrillation Eur. Heart J., October 1, 2004; 25(19): 1670 - 1671. [Full Text] [PDF]